SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-044007
Filing Date
2022-02-16
Accepted
2022-02-16 08:15:59
Documents
13
Period of Report
2022-02-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d334067d8k.htm   iXBRL 8-K 24586
2 EX-99.1 d334067dex991.htm EX-99.1 13992
  Complete submission text file 0001193125-22-044007.txt   169814

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA spro-20220216.xsd EX-101.SCH 2884
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20220216_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20220216_pre.xml EX-101.PRE 11726
7 EXTRACTED XBRL INSTANCE DOCUMENT d334067d8k_htm.xml XML 3476
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 22641557
SIC: 2834 Pharmaceutical Preparations